Roche Pharmaceutical Development and Sales Overview
YTD Sep 2022: Group sales +2% despite COVID-19 decline in Q3
Group sales +2% driven by Diagnostics division
•
•
Pharma with stable performance, key products compensating for LOEs and declining COVID-19 sales
Diagnostics with good growth momentum (+6%) including good base business growth (+6%)
Key products growing strongly; new launches with significant sales potential
•
•
•
Pharma growth drivers Ocrevus, Hemlibra, Evrysdi, Phesgo, Vabysmo and Tecentriq with strong momentum
Promising new launches with Vabysmo in ophthalmology and Polivy & Lunsumio in hematology
New launches of next generation of SARS-CoV-2 rapid antigen test 2.0, Prame immunohistochemistry assay for
melanoma and Digital LightCyler
Upcoming late-stage newsflow in 2022
·
Pharma: Gantenerumab in Alzheimer's disease; Venclexta in MM (t11;14); Vabysmo in RVO; Susvimo in DME & DR
.
Diagnostics: ElecsysⓇ pTau/AB42 ratio Gen2 CSF (FDA), cobas® 5800 (FDA)
Growth rates at CER (Constant exchange Rates); LOE-loss-of-exclusivity
Roche
6View entire presentation